In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment
Molecules · 2024
DOI: 10.3390/molecules29091909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Babatunji Emmanuel Oyinloye und 12 weiteren Autor:innen. Beteiligte Einrichtung: Phytomedicine, Biochemical Toxicology and Biotechnology Research Laboratories, Department of Biochemistry, College of Sciences, Afe Babalola Universi…. Hauptthemen laut MEDLINE: Azadirachta, Molecular Docking Simulation, Dihydroorotate Dehydrogenase, Schistosomiasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The burden of human schistosomiasis, a known but neglected tropical disease in Sub-Saharan Africa, has been worrisome in recent years. It is becoming increasingly difficult to tackle schistosomiasis with praziquantel, a drug known to be effective against all Schistosoma species, due to reports of reduced efficacy and resistance. Therefore, this study seeks to investigate the antischistosomal potential of phytochemicals from Azadirachta indica against proteins that have been implicated as druggable targets for the treatment of schistosomiasis using computational techniques. In this study, sixty-three (63) previously isolated and characterized phytochemicals from A. indica were identified from the literature and retrieved from the PubChem database. In silico screening was conducted to assess the inhibitory potential of these phytochemicals against three receptors (Schistosoma mansoni Thioredoxin glutathione reductase, dihydroorotate dehydrogenase, and Arginase) that may serve as therapeutic targets for schistosomiasis treatment. Molecular docking, ADMET prediction, ligand interaction, MMGBSA, and molecular dynamics simulation of the hit compounds were conducted using the Schrodinger molecular drug discovery suite. The results show that Andrographolide possesses a satisfactory pharmacokinetic profile, does not violate the Lipinski rule of five, binds with favourable affinity with the receptors, and interacts with key amino acids at the active site. Importantly, its interaction with dihydroorotate dehydrogenase, an enzyme responsible for the catalysis of the de novo pyrimidine nucleotide biosynthetic pathway rate-limiting step, shows a glide score and MMGBSA of −10.19 and −45.75 Kcal/mol, respectively. In addition, the MD simulation shows its stability at the active site of the receptor. Overall, this study revealed that Andrographolide from Azadirachta indica could serve as a potential lead compound for the development of an anti-schistosomal drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phytomedicine, Biochemical Toxicology and Biotechnology Research Laboratories, Department of Biochemistry, College of Sciences, Afe Babalola University, PMB 5454, Ado-Ekiti 360001, Nigeria.
- Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa.
- Institute of Drug Research and Development, S.E. Bogoro Center, Afe Babalola University, PMB 5454, Ado-Ekiti 360001, Nigeria.
- Department of Pharmacognosy and Natural Products, College of Pharmacy, Afe Babalola University, Ado-Ekiti 360001, Nigeria.
- College of Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan.
- Department of Epidemiology and Biostatistics, College of Public Health, Temple University, Philadelphia, PA 19121, USA.
ORCID-Profile: Babatunji Emmanuel Oyinloye, Emmanuel Ayodeji Agbebi, Sunday Amos Onikanni, Raphael Taiwo Aruleba, Tran Nhat Phong Dao, Olutunmise Victoria Owolabi, Deborah Tolulope Esan
Zitieren
APA
Oyinloye, B. E., Shamaki, D. E., Agbebi, E. A., Onikanni, S. A., Ubah, C. S., Aruleba, R. T., Dao, T. N. P., Owolabi, O. V., Idowu, O. T., Mathenjwa-Goqo, M. S., Esan, D. T., Ajiboye, B. O., & Omotuyi, O. I. (2024). In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment. Molecules. https://doi.org/10.3390/molecules29091909
Vancouver
Oyinloye BE, Shamaki DE, Agbebi EA, Onikanni SA, Ubah CS, Aruleba RT, et al. In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment. Molecules. 2024. doi:10.3390/molecules29091909
BibTeX
@article{Oyinloye2024,
author = {Oyinloye, Babatunji Emmanuel and Shamaki, David Ezekiel and Agbebi, Emmanuel Ayodeji and Onikanni, Sunday Amos and Ubah, Chukwudi Sunday and Aruleba, Raphael Taiwo and Dao, Tran Nhat Phong and Owolabi, Olutunmise Victoria and Idowu, Olajumoke Tolulope and Mathenjwa-Goqo, Makhosazana Siduduzile and Esan, Deborah Tolulope and Ajiboye, Basiru Olaitan and Omotuyi, Olaposi Idowu},
title = {In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29091909}
}
EUVIMED